JP2019517586A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517586A5
JP2019517586A5 JP2019516085A JP2019516085A JP2019517586A5 JP 2019517586 A5 JP2019517586 A5 JP 2019517586A5 JP 2019516085 A JP2019516085 A JP 2019516085A JP 2019516085 A JP2019516085 A JP 2019516085A JP 2019517586 A5 JP2019517586 A5 JP 2019517586A5
Authority
JP
Japan
Prior art keywords
substituted
release composition
sustained release
poly
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019516085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/035874 external-priority patent/WO2017210668A1/en
Publication of JP2019517586A publication Critical patent/JP2019517586A/ja
Publication of JP2019517586A5 publication Critical patent/JP2019517586A5/ja
Pending legal-status Critical Current

Links

JP2019516085A 2016-06-03 2017-06-05 カッパオピオイド受容体アゴニストの持続放出組成物 Pending JP2019517586A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345583P 2016-06-03 2016-06-03
US62/345,583 2016-06-03
PCT/US2017/035874 WO2017210668A1 (en) 2016-06-03 2017-06-05 Sustained release compositions of kappa-opioid receptor agonist

Publications (2)

Publication Number Publication Date
JP2019517586A JP2019517586A (ja) 2019-06-24
JP2019517586A5 true JP2019517586A5 (enExample) 2020-07-27

Family

ID=60478002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516085A Pending JP2019517586A (ja) 2016-06-03 2017-06-05 カッパオピオイド受容体アゴニストの持続放出組成物

Country Status (5)

Country Link
US (1) US20200316159A1 (enExample)
EP (1) EP3463306A4 (enExample)
JP (1) JP2019517586A (enExample)
CN (1) CN109789094A (enExample)
WO (1) WO2017210668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
CN114615976A (zh) 2019-08-07 2022-06-10 人福医药美国公司 κ阿片受体肽酰胺激动剂
EP4121083A4 (en) * 2020-03-18 2023-11-29 Cara Therapeutics, Inc. OLIGOSACCHARIDE FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS
JP7577265B2 (ja) 2020-06-25 2024-11-05 ヒューマンウェル ファーマシューティカル ユーエス，インコーポレイテッド 医学的障害の治療のためのペプチド
US12616732B2 (en) 2020-06-25 2026-05-05 Yichang Humanwell Pharmaceuticals Co., Ltd. Peptides for treatment of medical disorders
EP4322982A4 (en) * 2021-04-14 2025-03-19 Titan Pharmaceuticals, Inc. Kappa-opioid receptor agonist implants for treatment of pruritus
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
CN114873741B (zh) * 2022-05-31 2023-03-14 南京大学 一种脱氮缓释碳源材料及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
EP2040733A2 (en) * 2006-05-26 2009-04-01 Cara Therapeutics, Inc. Method for elevating prolactin in mammals
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
JP5244810B2 (ja) * 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
EP2152726B8 (en) * 2007-05-01 2015-02-18 Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP Analgesic compounds
ES2534847T3 (es) * 2010-09-02 2015-04-29 Grünenthal GmbH Forma de dosificación inviolable que comprende un polímero aniónico
HK1215934A1 (zh) * 2012-12-06 2016-09-30 Stealth Peptides International, Inc. 肽治疗剂及其使用方法

Similar Documents

Publication Publication Date Title
JP2012525393A5 (enExample)
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
US11058638B2 (en) Tyrosine derivatives and compositions comprising them
JP2018524298A5 (enExample)
JP2017518334A5 (enExample)
RU2012141951A (ru) Курс лечения с использованием агониста рецептора sip
JP2010077141A5 (enExample)
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
US12590162B2 (en) Cancer treatment
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
US20200316159A1 (en) Sustained release compositions of kappa-opioid receptor agonist
KR20210074315A (ko) P2x3 길항제를 사용한 소양증의 치료
JP2006518731A5 (enExample)
KR101307650B1 (ko) 구역에 대한 경피 방법 및 패치
CA2919078A1 (en) Treatment of pruritic conditions mediated through histamine h-4 receptors
JP2019531356A5 (enExample)
JP2019052094A5 (enExample)
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
JP2016523830A5 (enExample)
RU2313524C2 (ru) МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ
JP2019516722A5 (enExample)
RU2006138035A (ru) Применение производного фенотиазина для профилактики и/или лечения потери слуха
US9877978B2 (en) Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer
JP2013505940A5 (enExample)
JP2022517517A5 (enExample)